NEWS
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Vaccinex (Nasdaq: VCNX) will present topline data for its phase 1b/2 SIGNAL-AD study of pepinemab in Alzheimer's disease at the Alzheimer's Association International Conference on July 31, 2024. The study aims to evaluate the safety and efficacy of targeting reactive astrocytes with pepinemab, a SEMA4D blocking antibody.
Key outcomes will include safety, tolerability, and the impact on brain metabolic activity and astrocyte reactivity. The company hypothesizes that pepinemab can slow disease progression by blocking SEMA4D signaling in astrocytes. Vaccinex believes pepinemab could be an attractive alternative or complementary treatment to anti-Aβ antibodies like Leqembi™ or Kisunla™, given its different mechanism of action and good tolerability in previous trials.
Key outcomes will include safety, tolerability, and the impact on brain metabolic activity and astrocyte reactivity. The company hypothesizes that pepinemab can slow disease progression by blocking SEMA4D signaling in astrocytes. Vaccinex believes pepinemab could be an attractive alternative or complementary treatment to anti-Aβ antibodies like Leqembi™ or Kisunla™, given its different mechanism of action and good tolerability in previous trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1065Followers
68Following
7319Visitors
Follow